TLR9 and melanoma: Previously, we reported that splenic CD19+ DCs expressed IDO in response to melanoma growth and inflammatory insults that induce interferon type I production, including B7 and TLR9 ligands, DNA nanoparticles and apoptotic cells [13–16, 21, 22].